This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
Since 2012, the Cancer Research Institute has partnered with MedImmune, a member of the AstraZeneca Group, to advance clinical trials to test novel combinations of cancer immunotherapies. CRI is conducting trials using investigational drugs that MedImmune has provided through this partnership from its product pipeline.
AstraZeneca’s support of educational programming includes funding the 2017 Immunotherapy Patient Summit series and multi-year funding for Cancer Immunotherapy Month. Additionally, AstraZeneca provided multi-year support for the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference and Annual Awards Dinner. AstraZeneca has also supported the CRI Irvington Postdoctoral Fellowship Program.
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
Dr. Benjamin Vincent recaps highlights from Day 4 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference, covering cancer vaccines and innovative technologies to study tumor immunity.
Dr. E. John Wherry dicusses cell therapies and the cancer ecosystem during Day 3 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22).